Vicapsys Life Sciences is a pre-revenue, early-stage biotech developing therapeutics based on CXCL12, a naturally occurring protein, licensed from Massachusetts General Hospital. The company's core technology uses CXCL12 to create a localized immune-protective zone around transplanted cells, tissues, or implanted devices. Vicapsys has two product lines in development: VICAPSYN, targeting transplantation therapies — primarily Type 1 Diabetes — through an encapsulated human islet cell cluster designed to restore insulin production when implanted; and VYBRIN, targeting fibrosis prevention, including post-surgical abdominal adhesions, coating of implantable devices, and wound healing in diabetic patients. The business model is a classic biotech IP licensing play: Vicapsys licenses the underlying patents from MGH, advances the technology through preclinical and clinical development, and aims to commercialize or sublicense approved products. Key obligations under the MGH license include an annual fee, a 1% royalty on net sales, and milestone payments tied to sales thresholds. Vicapsys has no products on the market, no revenues, and only two employees. The company has not yet filed an IND or initiated any clinical trials, has spent roughly $15,000/year on R&D, and has missed several MGH-imposed development milestones, which it is currently renegotiating. Manufacturing is planned to be outsourced to third-party contract manufacturers.